A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 (NCT06003231)
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. In the first part of the study, participants must have tumors that have a marker called HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. In this study, all participants will get DV once every 2 weeks. This study is being done to see if DV works to treat different types of solid tumors that express HER2. It will also test how safe the drug is for participants. This trial will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Who can join: Review the eligibility criteria below.
Location: Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (96 Sites)
Showing the first 25 of 96 sites.
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Gilbert, Arizona
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Glendale, Arizona
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Mesa, Arizona
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Mesa, Arizona
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Phoenix, Arizona
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Scottsdale, Arizona
- Valkyrie Clinical Trials(Additional Suite) — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California Davis Comprehenvise Cancer Center — Sacramento, California
- University of California Davis Medical Center — Sacramento, California
- Providence Medical Foundation — Santa Rosa, California
- PCM Trails — Denver, Colorado
- PCM Trials — Denver, Colorado
- Smilow Cancer Hospital at Yale - New Haven — New Haven, Connecticut
- Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut
- Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut
- Yale Cancer Center — New Haven, Connecticut
- Smilow Cancer Hospital Care Center at Trumbull — Trumbull, Connecticut
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables, Florida
- University of Miami Hospital and Clinics Deerfield Beach — Deerfield Beach, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University of Miami Hospital and Clinics — Miami, Florida
- Sylvester Comprehensive Cancer Center - Kendall — Miami, Florida
- Sylvester Comprehensive Cancer Center Plantation — Plantation, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.